EVA is registered trademark of Stern Stewart.
Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.
Paying user area
Try for free
Danaher Corp. pages available for free this week:
- Income Statement
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Current Ratio since 2005
- Total Asset Turnover since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Danaher Corp. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Economic Profit
| 12 months ended: | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|---|
| Net operating profit after taxes (NOPAT)1 | ||||||
| Cost of capital2 | ||||||
| Invested capital3 | ||||||
| Economic profit4 | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 NOPAT. See details »
2 Cost of capital. See details »
3 Invested capital. See details »
4 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= – × =
The period under review demonstrates a consistent pattern of negative economic profit. Net operating profit after taxes (NOPAT) exhibited initial growth, followed by a substantial decline. The cost of capital increased steadily for three years before stabilizing, while invested capital showed an initial increase followed by a decrease in the most recent year. These factors combined to produce consistently negative economic profit values throughout the observed timeframe.
- NOPAT Trend
- Net operating profit after taxes increased from US$4,986 million in 2020 to US$6,722 million in 2021, and further to US$6,866 million in 2022. However, a significant decrease was observed in 2023, falling to US$3,099 million, with a slight recovery to US$3,391 million in 2024. This suggests a weakening of operational profitability in recent years.
- Cost of Capital Trend
- The cost of capital experienced a steady increase from 13.54% in 2020 to 14.48% in 2023. In 2024, the cost of capital decreased marginally to 14.41%. This indicates a rising cost of funding the company’s operations, potentially due to changing market conditions or increased risk perception.
- Invested Capital Trend
- Invested capital increased from US$67,123 million in 2020 to US$78,342 million in 2022, indicating expansion of the company’s asset base. However, it decreased to US$73,131 million in 2024, potentially reflecting asset sales, reduced investment, or depreciation exceeding new investments.
- Economic Profit Trend
- Economic profit remained negative throughout the period, ranging from -US$3,552 million to -US$8,274 million. The most substantial negative economic profit occurred in 2023, at -US$8,274 million. While the negative economic profit lessened slightly in 2024 to -US$7,144 million, it remained considerably below the levels observed in 2020 and 2021. This consistently negative economic profit suggests that the company is not generating returns exceeding its cost of capital.
The combination of increasing cost of capital and fluctuating NOPAT, coupled with substantial invested capital, resulted in persistent negative economic profit. The decline in NOPAT in 2023, coinciding with the peak cost of capital, significantly worsened economic profit. The slight recovery in NOPAT in 2024 did not fully offset the impact of the high cost of capital and the decrease in invested capital, resulting in continued negative economic profit.
Net Operating Profit after Taxes (NOPAT)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Elimination of deferred tax expense. See details »
2 Addition of increase (decrease) in allowance for doubtful accounts.
3 Addition of increase (decrease) in contract liabilities.
4 Addition of increase (decrease) in equity equivalents to net earnings.
5 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =
6 2024 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =
7 Addition of after taxes interest expense to net earnings.
8 2024 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =
9 Elimination of after taxes investment income.
10 Elimination of discontinued operations.
- Net Earnings
-
The net earnings demonstrate a significant upward trend from 2020 to 2022, increasing from 3,646 million US dollars in 2020 to a peak of 7,209 million US dollars in 2022. This represents nearly a doubling over the two-year period, indicating strong profitability growth.
However, there is a notable decline starting in 2023, with net earnings decreasing to 4,764 million US dollars, followed by a further decline to 3,899 million US dollars in 2024. This reversal suggests challenges impacting profitability or potential one-time events reducing net income in the latter periods.
- Net Operating Profit After Taxes (NOPAT)
-
NOPAT exhibits an increasing trend from 2020 through 2022, rising from 4,986 million US dollars in 2020 to 6,866 million US dollars in 2022. This indicates improving operating performance and effective tax management in this period.
Contrary to net earnings, there is a sharp decline in NOPAT in 2023 to 3,099 million US dollars, reflecting a substantial decrease in operating profitability. However, in 2024, NOPAT slightly recovers to 3,391 million US dollars, suggesting a partial operational improvement compared to the previous year.
- Overall Trends and Insights
-
Both net earnings and NOPAT show robust growth from 2020 to 2022, indicating a period of strong financial performance. The decline starting in 2023 is pronounced for both metrics, although net earnings remain relatively higher than NOPAT in both 2023 and 2024. This divergence may point toward increased non-operating income or variations in tax expense or extraordinary items impacting net earnings differently.
The partial rebound in NOPAT in 2024, combined with the continuing decline in net earnings, suggests operational improvements are underway, but other factors are continuing to suppress overall profitability. Overall, the data reflects a challenging environment in the most recent years following a period of solid growth.
Cash Operating Taxes
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The financial data reflects the tax-related expenses of the company over a five-year period. There are two primary tax metrics provided: Income tax provision and Cash operating taxes, both measured in millions of US dollars.
- Income Tax Provision
- This metric experienced a notable increase from 849 million USD in 2020 to a peak of 1,251 million USD in 2021. After this peak, the provision declined to 1,083 million USD in 2022 and continued to decrease steadily through 2023 and 2024, reaching 747 million USD. This pattern suggests a reduction in tax liabilities or changes in taxable income and accounting estimates after 2021.
- Cash Operating Taxes
- Cash operating taxes started at 380 million USD in 2020, then surged significantly to 1,534 million USD in 2021 and further increased to reach 1,684 million USD in 2022. The upward trend continued in 2023, peaking at 2,032 million USD. However, in 2024, there was a substantial decline to 1,274 million USD. This indicates an initial escalation in cash tax payments over the 2021-2023 period, followed by a marked reduction in the most recent year.
Comparing both tax measures reveals a divergence in their trends, especially after 2021. While the income tax provision decreased steadily from 2021 onwards, cash operating taxes rose sharply for three years before declining in the final year. This divergence could point to timing differences in tax payments versus accrued tax expenses, changes in deferred tax assets or liabilities, or adjustments in tax planning strategies. The significant fluctuations in cash operating taxes imply periods of higher actual tax cash outflows, which may have liquidity implications.
Overall, the data suggests the company experienced fluctuating tax obligations, with peak tax provisions in 2021 and peak cash taxes in 2023, followed by declines in both in 2024. The contrasting movements between provision and cash taxes highlight the complexity of the company's tax situation over these years, warranting further examination of underlying causes such as tax policy changes, profitability shifts, or one-time tax events.
Invested Capital
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Addition of capitalized operating leases.
2 Elimination of deferred taxes from assets and liabilities. See details »
3 Addition of allowance for doubtful accounts receivable.
4 Addition of contract liabilities.
5 Addition of equity equivalents to total Danaher stockholders’ equity.
6 Removal of accumulated other comprehensive income.
7 Subtraction of investments.
- Total reported debt & leases
-
There is a consistent downward trend in total reported debt and leases over the five-year period. The debt decreased from US$22,178 million in 2020 to US$17,146 million in 2024, reflecting a reduction of approximately 22.6%. This suggests a progressive deleveraging strategy or improved debt management, potentially reducing financial risk and interest expenses.
- Total Danaher stockholders’ equity
-
Stockholders’ equity shows an overall upward trend from US$39,766 million in 2020 to a peak of US$53,486 million in 2023. However, a decline is observed in 2024, dropping to US$49,543 million. The initial continuous growth may indicate profitable operations, retained earnings accumulation, or equity issuance. The decrease in 2024 could be due to dividends, share buybacks, or losses, warranting further investigation.
- Invested capital
-
Invested capital steadily increased from US$67,123 million in 2020 to US$78,561 million in 2023, suggesting ongoing investment in assets or operations. In 2024, it declined to US$73,131 million. The upward movement aligns with growth or expansion strategies, while the recent decrease could signal asset disposals, reduced investment activity, or operational optimization.
- Summary
-
The financial data indicates that the company has been actively managing its capital structure by decreasing debt levels while increasing equity and invested capital in the initial years. The modest reduction in equity and invested capital in the final year could imply a strategic shift or response to market conditions. Overall, the trends suggest enhanced financial stability with cautious reinvestment, although the 2024 changes merit additional scrutiny to understand underlying causes.
Cost of Capital
Danaher Corp., cost of capital calculations
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| 4.75% Mandatory Convertible Preferred Stock, Series A | ÷ | = | × | = | |||||||||
| 5.00% Mandatory Convertible Preferred Stock, Series B | ÷ | = | × | = | |||||||||
| Notes payable and long-term debt3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2024-12-31).
1 US$ in millions
2 Equity. See details »
3 Notes payable and long-term debt. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| 4.75% Mandatory Convertible Preferred Stock, Series A | ÷ | = | × | = | |||||||||
| 5.00% Mandatory Convertible Preferred Stock, Series B | ÷ | = | × | = | |||||||||
| Notes payable and long-term debt3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2023-12-31).
1 US$ in millions
2 Equity. See details »
3 Notes payable and long-term debt. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| 4.75% Mandatory Convertible Preferred Stock, Series A | ÷ | = | × | = | |||||||||
| 5.00% Mandatory Convertible Preferred Stock, Series B | ÷ | = | × | = | |||||||||
| Notes payable and long-term debt3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2022-12-31).
1 US$ in millions
2 Equity. See details »
3 Notes payable and long-term debt. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| 4.75% Mandatory Convertible Preferred Stock, Series A | ÷ | = | × | = | |||||||||
| 5.00% Mandatory Convertible Preferred Stock, Series B | ÷ | = | × | = | |||||||||
| Notes payable and long-term debt3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2021-12-31).
1 US$ in millions
2 Equity. See details »
3 Notes payable and long-term debt. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| 4.75% Mandatory Convertible Preferred Stock, Series A | ÷ | = | × | = | |||||||||
| 5.00% Mandatory Convertible Preferred Stock, Series B | ÷ | = | × | = | |||||||||
| Notes payable and long-term debt3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2020-12-31).
1 US$ in millions
2 Equity. See details »
3 Notes payable and long-term debt. See details »
4 Operating lease liability. See details »
Economic Spread Ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Economic profit1 | ||||||
| Invested capital2 | ||||||
| Performance Ratio | ||||||
| Economic spread ratio3 | ||||||
| Benchmarks | ||||||
| Economic Spread Ratio, Competitors4 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Economic profit. See details »
2 Invested capital. See details »
3 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =
4 Click competitor name to see calculations.
The economic spread ratio exhibited a consistent decline over the five-year period. Initially negative, the ratio worsened significantly from 2020 to 2023 before showing a slight improvement in 2024, though remaining substantially negative. This trend is closely linked to the movement of economic profit and invested capital.
- Economic Spread Ratio
- The economic spread ratio decreased from -6.11% in 2020 to -10.53% in 2023, representing a substantial deterioration in the relationship between returns generated and capital employed. A modest recovery to -9.77% occurred in 2024, but the ratio remained considerably lower than its 2020 level. This indicates an increasing gap between the cost of capital and the returns generated from invested capital.
Economic profit consistently remained negative throughout the observed period. The magnitude of the negative economic profit increased from US$4,100 million in 2020 to US$8,274 million in 2023, before decreasing to US$7,144 million in 2024. This suggests that the company’s returns were insufficient to cover its cost of capital in each year, and the shortfall widened considerably until 2023.
- Invested Capital
- Invested capital generally increased from US$67,123 million in 2020 to US$78,561 million in 2023. However, a decrease to US$73,131 million was observed in 2024. The increase in invested capital, coupled with consistently negative economic profit, likely contributed to the worsening economic spread ratio between 2020 and 2023. The slight decrease in invested capital in 2024 may have partially mitigated the negative trend in the economic spread ratio.
The combined effect of increasing invested capital (until 2023) and declining economic profit resulted in a progressively more negative economic spread ratio. While the economic profit decreased in magnitude in 2024, the economic spread ratio remained significantly negative, indicating continued underperformance relative to the cost of capital.
Economic Profit Margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Economic profit1 | ||||||
| Sales | ||||||
| Add: Increase (decrease) in contract liabilities | ||||||
| Adjusted sales | ||||||
| Performance Ratio | ||||||
| Economic profit margin2 | ||||||
| Benchmarks | ||||||
| Economic Profit Margin, Competitors3 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Economic profit. See details »
2 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Adjusted sales
= 100 × ÷ =
3 Click competitor name to see calculations.
The economic profit margin exhibited a consistently negative trend over the five-year period. While negative economic profit was present throughout, the magnitude of the loss increased significantly in later years. Adjusted sales demonstrated initial growth followed by a decline.
- Economic Profit Margin
- The economic profit margin began at -17.91% in 2020 and improved to -11.89% in 2021. However, this improvement was short-lived, as the margin deteriorated to -13.76% in 2022. A substantial decrease was observed in 2023, with the margin reaching -34.58%. This negative trend continued into 2024, with the economic profit margin reported at -30.16%. The increasing negativity suggests a widening gap between returns generated and the cost of capital.
- Economic Profit
- Economic profit itself was negative across the entire period. The absolute value of the loss decreased from US$4,100 million in 2020 to US$3,552 million in 2021. However, it then increased to US$4,339 million in 2022. A significant increase in the absolute loss occurred in 2023, reaching US$8,274 million, before decreasing slightly to US$7,144 million in 2024. This pattern mirrors the trend observed in the economic profit margin.
- Adjusted Sales
- Adjusted sales increased from US$22,895 million in 2020 to US$29,862 million in 2021, representing a period of growth. Sales continued to rise, reaching US$31,528 million in 2022. However, a notable decline in adjusted sales was observed in 2023, falling to US$23,927 million. This downward trend persisted into 2024, with sales reported at US$23,692 million. The decline in sales, coupled with consistently negative economic profit, contributed to the worsening economic profit margin.
The combination of declining sales and persistent negative economic profit indicates potential challenges in generating returns exceeding the cost of capital. The substantial deterioration in the economic profit margin in 2023 warrants further investigation.